Gunnar Tafjord

  • Consultant; MD
 

Publications 2022

Møller CT, Fosså SD, Tafjord G, Babigumira R, Berge V, Andreassen BK (2022)
Primary versus secondary muscle-invasive bladder cancer: survival after curative treatment
Scand J Urol, 56 (3), 214-220
DOI 10.1080/21681805.2022.2056633, PubMed 35506475

Publications 2021

Aljabri B, Lilleby W, Switlyk MD, Tafjord G (2021)
Restart of androgen deprivation therapy after goserelin induced pituitary apoplexy in a patient with disseminated prostate cancer a case report and five-years follow-up
Urol Case Rep, 37, 101648
DOI 10.1016/j.eucr.2021.101648, PubMed 33868933

Publications 2018

Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W (2018)
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort
Radiother Oncol, 132, 211-217
DOI 10.1016/j.radonc.2018.10.013, PubMed 30389241

Publications 2015

Lilleby W, Narrang A, Tafjord G, Vlatkovic L, Russnes KM, Stensvold A, Hole KH, Tran P, Eilertsen K (2015)
Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy
Radiat Oncol, 10, 232
DOI 10.1186/s13014-015-0540-3, PubMed 26577452

Publications 2011

Lilleby W, Tafjord G, Raabe NK (2011)
Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer
Int J Radiat Oncol Biol Phys, 83 (3), 933-9
DOI 10.1016/j.ijrobp.2011.08.028, PubMed 22138456

Publications 2008

Raabe NK, Lilleby W, Tafjord G, Aström L (2008)
[High dose rate brachytherapy in prostate cancer in Norway]
Tidsskr Nor Laegeforen, 128 (11), 1275-8
PubMed 18511969

Page visits: 40